In June 2026, the Ministry of Agriculture and Rural Affairs officially issued a veterinary biologics clinical trial approval. The feline GnRH protein (E. coli-derived) clinical trial project, led by Prof. Cong Feng of the College of Animal Science and Technology, Zhongkai University of Agriculture and Engineering, relying on the platform of the Guangdong Provincial Engineering Technology Research Center for Intelligent Biosecurity Prevention and Control of Aquatic Animal Diseases, and jointly declared with Changzhou Fubang Biopharmaceutical Co., Ltd. and Shangqiu Meilan Bio Co., Ltd., was approved. This is the first time the College of Animal Science and Technology has received a veterinary biologics clinical trial approval from the Ministry of Agriculture and Rural Affairs, marking a key staged achievement of our college in the field of reproductive regulation biologics R&D for companion animals.
Adapting to the Pet Economy, Laying Out Innovative Veterinary Drugs for Companion Animals
In recent years, the domestic pet industry has flourished, and the demand of pet-owning households for canine and feline health management has continued to expand. Although traditional surgical castration/neutering can effectively control animal reproduction and reduce the risk of reproductive system diseases, it carries risks such as anesthesia, post-operative pain and the burden of care management. Biologics centered on GnRH (gonadotropin-releasing hormone) can affect sex hormone secretion through immune or chemical regulation, providing a non-surgical alternative for companion animal reproductive health management, with broad market prospects.
Industry-University-Research Collaboration: Bridging the Key Link from Lab to Clinic
The approved feline GnRH protein (E. coli-derived) clinical trial project adopts a mature E. coli prokaryotic expression system, with clear objectives and controllable processes. Prof. Cong Feng's team is responsible for core antigen design and pre-clinical research, Fubang Biopharmaceutical undertakes pilot production and quality research, and Meilan Bio cooperates in clinical trial implementation. The three parties complement each other's advantages, forming a complete chain of "university R&D — enterprise transformation — clinical verification."
Clinical Trial Approval: The "Pass" from Research to Product
The veterinary biologics clinical trial approval is a statutory permit issued by the Ministry of Agriculture and Rural Affairs before systematically evaluating the safety and efficacy of a candidate product, and is a key node for moving from laboratory research to commercial registration. Obtaining this approval means that the feline GnRH protein project has passed the preliminary multi-dimensional evaluation of pharmaceutics, toxicology and immunology, and is qualified to conduct standardized clinical trials at designated trial units and under designated clinical scenarios.
Next Step: Accelerate Clinical Verification, Serve Pet Health
The College of Animal Science and Technology stated that it will continue to use Party building to lead scientific research innovation, base itself on the characteristic professional advantages of animal husbandry and veterinary medicine, keep pace with the development trend of the pet health industry, deepen the field of companion animal disease prevention and reproductive regulation, and accelerate the R&D and commercialization of various innovative veterinary biologics. Qianxun Bio will also continue to pay attention to and participate in relevant technical services and achievement transformation, empowering the high-quality development of the domestic veterinary drug industry with original scientific research technology.